Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150

Skye Bioscience, Inc.

John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
Board approved repricing of 2,420,978 outstanding options held by full-time employees to $0.6150/share (closing price on repricing date).
Repriced options previously had exercise prices ranging from $1.055 to $14.56; include 1,103,959 options held by CEO Punit Dhillon and 396,295 held by COO Tuan Diep.
Option repricing intended to retain and motivate eligible participants without additional dilution or cash compensation.
Master Services Agreement with Lohman & Associates entered; Sharp will serve as principal financial and accounting officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.